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ABSTRACT
Since rifampicin resistance is a surrogate marker for multidrug-resistant Mycobacterium tuberculosis
(MDRTB), the present study aimed to investigate rpoB mutations conferring rifampicin resistance in
M. tuberculosis strains from Thailand, and to develop a rapid, inexpensive and simple PCR-based
method for rapid detection of MDRTB. Overall, 267 M. tuberculosis isolates, including 143 MDRTB
isolates, were investigated. Isolates of the Beijing strain predominated among the MDRTB isolates
(79.1%), but accounted for only 45.5% of the susceptible isolates. Mutations in the rpoB gene were found
most commonly at codons 531, 526 and 516 (58%, 25.2% and 9.1%, respectively). A multiplex allele-
speciﬁc PCR was developed and tested with 216 clinical isolates. In comparison with the proportion
method, the method showed 94.2% sensitivity and 100% speciﬁcity, and had a 100% positive predictive
value and a 95% negative predictive value, which suggested that this method could be useful for
screening for MDRTB, particularly in resource-limited countries.
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INTRODUCTION
Tuberculosis (TB) remains a major public health
problem worldwide. In Thailand, the incidence
of TB cases in 2004 was 142 ⁄ 100 000, with a
mortality rate of 19 ⁄ 100 000. Resistance to at
least rifampicin and isoniazid, designated as
multidrug-resistant Mycobacterium tuberculosis
(MDRTB), occurred at a frequency of 0.9% and
20% among new TB cases and previously treated
TB cases, respectively, and Thailand is ranked
17th in a list of 22 high-burden countries [1]. In
the clinical setting, early detection of MDRTB is
important in selecting an appropriate treatment
regimen to reduce mortality and morbidity and
prevent the development of further resistance and
the spread of resistant strains. Phenotypic identi-
ﬁcation of MDRTB is still a time-consuming
method, requiring several days or weeks to obtain
a result, which may jeopardise efforts to control
this disease.
Genotypic analysis is the most rapid method
currently available for identiﬁcation of MDRTB
strains [2]. Rifampicin is one of the most potent
anti-TB agents, and rapid detection of rifampicin
resistance is of particular importance, since >90%
of rifampicin-resistant isolates are also resistant to
isoniazid. Therefore, rifampicin resistance repre-
sents a valuable surrogate marker for MDRTB [3].
Resistance to rifampicin has been demonstrated
to result from mutation(s) in rpoB, the RNA
polymerase b-subunit-encoding gene [4]. Several
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sequencing studies have shown that 90–95% of
rifampicin-resistant M. tuberculosis isolates have a
mutation within an 81-bp hot-spot region (codons
507–533; Escherichia coli numbering) of the rpoB
gene. A single nucleotide substitution in codon
531 is the most frequent mutation associated with
rifampicin resistance [5–11]. However, the distri-
bution and frequency of mutations differ among
genotypes and strains isolated from different
geographical areas; e.g., a mutation at Ser531 in
multidrug-resistant (MDR)-Beijing genotype iso-
lates from Germany, Kazakhstan and Russia has
been found to occur more frequently than in non-
Beijing genotypes [12–14]. In contrast, studies of
MDR isolates from East Asian countries, e.g.,
China, Korea and Taiwan, have revealed that the
mutation rate of Ser531 was either lower in Beijing
strains [15] or did not differ signiﬁcantly among
Beijing and non-Beijing MDR strains [16].
In Thailand, previous data from a nationwide
study have revealed that Beijing family strains
were circulating in the country, but that they
were not signiﬁcantly more frequent than other
genotypes and were not associated with MDRTB
[17]. However, only a small number of MDRTB
strains were investigated, and recent evidence
has suggested an increasing prevalence of Beijing
strains in TB patients (personal unpublished
data), which accords with other reports that
Beijing family strains are predominant among
M. tuberculosis isolates in East and Southeast Asia
[18–20]. It has been hypothesised that the Beijing
strains have evolved unique properties [19],
including the ability to evade the protective effect
of Mycobacterium bovis bacille Calmette-Gue´rin
vaccination [21], to disseminate more efﬁciently
[18], and to acquire drug resistance more fre-
quently than non-Beijing strains [22,23]. Further-
more, little is known concerning the distribution
of rpoB mutations among MDRTB strains circu-
lating in Thailand. Characterisation of these
strains would provide basic epidemiological
information, which could be applied to the
development of a rapid method for identiﬁcation
of MDRTB. Therefore, the aims of the present
study were to investigate the rpoB mutations
conferring rifampicin resistance in Thai MDRTB
strains, as well as the association between drug
resistance and the Beijing genotype. Based on
these results, a rapid, inexpensive and simple




In total, 267 M. tuberculosis isolates (one isolate ⁄patient),
including 154 rifampicin-resistant (143 MDR and 11 mono-
resistant) and 113 rifampicin-susceptible isolates, were ran-
domly selected from among 5094 isolates (318 MDR and 4776
rifampicin-susceptible isolates) obtained from the sputa of
patients with suspected TB at the Molecular Mycology and
Mycobacteriology Laboratory (Drug-resistant Tuberculosis
Research Fund), Department of Microbiology, Faculty of
Medicine, Siriraj Hospital, Mahidol University, Thailand,
during 2003–2005. The patients included new and previously
treated patients of known and unknown human immuno-
deﬁciency virus status. None of the isolates was obtained as
part of a TB outbreak. The patients came from 53 of the 76
provinces of Thailand, thus representing all regions of the
country. Mycobacteria were cultured on Lo¨wenstein–Jensen
medium and incubated at 37C for 3–4 weeks. Species iden-
tiﬁcation and anti-mycobacterial susceptibility testing were
performed using an in-house one-tube multiplex PCR [24] and
the standard proportion method [25,26].
Ampliﬁcation of the rpoB gene
Genomic DNA was isolated using the boiling method as
described previously [27]. For sequence analysis, two regions
of the rpoB gene were investigated, one at the beginning and the
other at the hot-spot region of the rpoB gene. First, a 365-bp
fragment at the beginning of the rpoB gene covering codon 146
(E. coli numbering equivalent to codon 176 of M. tuberculosis
rpoB) was ampliﬁed using primers TB-176-F and TB-176-R [28].
Second, a 749-bp fragment comprising the complete region from
cluster I (hot-spot region; codons 507–533, E. coli numbering) to
cluster III was ampliﬁed using primers TBB-1 and TBB-2 [6].
Primer sequences used are listed in Table 1. Each 50-lL reaction
mixture contained 5 lL crude genomic DNA, 10 mM Tris-HCl
(pH 8.4), 50 mMKCl, 1.5 mM (for TBB-1 ⁄TBB-2) or 2.5 mM (for
TB-176-F ⁄TB-176-R) MgCl2, 200 lM each dNTP, 30 lM each
primer, and 1 U Taq DNA polymerase (Fermentas Inc., Hano-
ver, MD, USA). PCRs comprised 94C for 5 min, followed by 40
cycles of 94C for 45 s, 64C for 1 min and 72C for 2 min, with a
ﬁnal extension at 72C for 7 min.
DNA sequencing analysis
Ampliﬁed rpoB gene products were puriﬁed using a MinElute
Gel Extraction Kit (Qiagen, Hilden, Germany) and sent to
Macrogen Sequencing Service (Macrogen, Seoul, Korea) for
Table 1. Primer sequences used in this study




TBB-2 TGCATCAC AGTGATGTAGTCG [6]
RPOF TCGCCGCGATCAAGGAGT This study
RPOR-1 GGGGTTTCGATCGGGCA This study
A511F CGGCACCAGCCAGCT This study
A516F CTGAGCCAATTCATGGA This study
A526F GTCGGGGTTGACCCA [31]
A531F CAAGCGCCGACTGTC This study
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DNA sequencing. The PCR primers were also used as
sequencing primers. The DNA sequences obtained were
compared with the wild-type rpoB sequence using Clustal W
software [29].
Spoligotyping
Spoligotyping was performed using a commercial kit (Isogen
Bioscience BV, Maarsen, The Netherlands) according to the
method described previously [30]. Reverse blotting analysis of
spacer sequences in the direct repeat region was performed
using a streptavidin–horseradish peroxidase-enhanced chemi-
luminescence assay (Amersham Pharmacia Biotech, Roos-
endaal, The Netherlands). Isolates belonging to the Beijing
family were identiﬁed on the basis of nine or fewer copies of
spacers 35–43 between direct repeat sequences ﬂanking IS6110.
Rapid identiﬁcation of mutations by the multiplex
allele-speciﬁc (MAS)-PCR method
A genotypic method able to identify the most frequent
mutations conferring rifampicin resistance was developed as
part of this study. A MAS-PCR that applied the principle and
concept described previously [31] was established using ﬁve
pairs of primers, one of which was based on an M. tuberculosis
complex-speciﬁc sequence, and the others which were
codon-speciﬁc sequences (codons 511, 516 526, and 531).
Fig. 1 shows a schematic view of the method; primer
sequences are listed in Table 1. PCR was performed in 50-lL
reaction mixtures containing 10 mM Tris-HCl (pH 8.4), 50 mM
KCl, 2.5 mM MgCl2, gelatin 0.001% w ⁄v, 200 lM each dNTP,
0.02 lM RPOF, 0.5 lM A511F, 7.5 lM A516F, 2.5 lM A526F,
40 lM A531F and 30 lM RPOR-1 primers (Table 1), 2 U Taq
DNA polymerase (Fermentas Inc.) and 5 lL crude DNA
extract. PCR conditions comprised 94C for 7 min, followed
by 15 cycles of 94C for 1 min, 70C for 1 min and 72C
for 1.5 min, followed by 35 cycles of 94C for 1 min, 63C for
1 min and 72C for 1 min, with a ﬁnal extension at 72C for
10 min. Ampliﬁed products (7 lL) were analysed by gel
electrophoresis on Nusieve 3:1 agarose (Cambrex Bio Science
Rockland, Inc., Rockland, ME, USA) 4% w ⁄v gels (2.5 V ⁄ cm)
with a 25-bp DNA ladder (Invitrogen, Carlsbad, CA, USA) for
size determination. Based on the principle that the 3¢-end of
the allele-speciﬁc primer locates at the second base of each
wild-type codon, the presence of mutations in a codon results
in mismatching and the absence of the allele-speciﬁc band
under stringent PCR conditions. Positive (rifampicin-resistant)
and negative (rifampicin-susceptible) results were interpreted
according to the absence and presence, respectively, of codon-
speciﬁc ampliﬁcation bands. The rifampicin-susceptible strain
M. tuberculosis H37Rv was used as a control strain that yielded
all speciﬁc bands; the 196-bp M. tuberculosis complex-speciﬁc
band was used as an internal control to monitor the presence
of PCR inhibitors. The method was assessed by comparing the
results obtained with those obtained by the proportional
method and calculating the sensitivity, speciﬁcity, positive
predictive value (PPV) and negative predictive value (NPV).
Statistical analysis
Data were analysed using SPSS software (SPSS Inc., Chicago
IL, USA). Differences were compared using chi-squared tests.
RESULTS
Resistance patterns and prevalence of Beijing
strains among M. tuberculosis isolates
Of the 267 M. tuberculosis isolates investigated,
113 were susceptible to at least rifampicin and
isoniazid, 143 were MDRTB, and 11 were rifam-
picin-mono-resistant. The susceptibility patterns
of the isolates studied are summarised in Table 2.
Spoligotyping was performed for 153 of 154
rifampicin-resistant isolates; of these, 121
(79.1%) were revealed to be Beijing strains. In
contrast, of 112 rifampicin-susceptible isolates
that were spoligotyped, only 51 (45.5%) were
revealed to be Beijing strains.
Distribution of rpoB gene mutations
All 154 rifampicin-resistant isolates carried muta-
tions in either the hot-spot region or at the
N-terminal part of the rpoB gene (Tables 3 and 4).
A531FA516FA511F RPOF RPOR-1A526F
115-bp band 





Fig. 1. Schematic view of the rpoB gene fragments targeted
by the multiplex allele-speciﬁc (MAS)-PCR. Short arrows
depict the primers, and long double-headed arrows rep-
resent the PCR products obtained with the Mycobacterium
tuberculosis complex-speciﬁc primers (196 bp) or the allele-
speciﬁc primers (176, 162, 129 or 115 bp, respectively);
ﬁgure not to scale.
Table 2. Drug susceptibility proﬁles of 267 Mycobacterium
tuberculosis isolates from Thailand
Susceptibility pattern No. of isolates Total




RIF + INH 52
RIF + INH + EMB 14
RIF + INH + STR 26
RIF + INH + EMB + STR 51
Total 267
RIF, rifampicin; INH, isoniazid; EMB, ethambutol; STR, streptomycin; R, resistant.
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Single point mutations resulting in amino-acid
substitutions were found in 146 (94.8%) isolates,
and eight (5.2%) isolates had double mutations.
Of 143 MDRTB isolates, 133 contained single
point mutations in the hot-spot region, with 11
different genotypes, and two isolates had a
mutation at codon 146 (Gln146Lys). Six double
mutations and two deletions were found in eight
isolates (Table 3). Amino-acid substitutions at
codon 531 occurred at the highest frequency
(58.0%), followed by those at codon 526 (25.2%)
and codon 516 (9.1%). The remaining isolates had
mutations at codons 513 (2.1%), 533 (2.1%) and
522 (0.7%). Only a Ser ﬁ Leu substitution was
found at codon 531. Codon 526 showed the
highest variability of mutations, with four differ-
ent nucleotide substitutions. Substitution of
histidine with tyrosine accounted for 52.8% of
the mutations at this codon.
Among mono-resistant isolates, ten of 11 rif-
ampicin-mono-resistant isolates had single point
mutations at codon 531 (36.4%), codon 526
(45.4%) or codon 516 (9.1%); the mutation at
codon 146 was found in one isolate (Table 4). As
with the MDRTB isolates, codon 526 showed the
highest variability of mutation, with a His ﬁ Tyr
substitution being the most common. Although
the number of rifampicin-mono-resistant isolates
was too small for statistical analysis, it was
interesting that mutations at codon 526 were
found at a higher frequency than those at codon
531 (45.4% vs. 36.4%). Thirty of 113 rifampicin-
susceptible isolates were sequenced, and none
showed any mutations in the rpoB gene fragment
sequenced.
Correlation of genotypes and rpoB mutations
Among the 121 rifampicin-resistant Beijing iso-
lates, 116 (95.9%) contained single mutations,
while double mutations and deletions were found
in three (2.5%) and two (1.6%) isolates, respec-
tively. Thirty (93.8%) and two (6.2%) of 32 non-
Beijing isolates had single mutations and double
mutations, respectively (Tables 3 and 4).
Of 142 MDRTB isolates of known genotype, 112
(78.9%) were Beijing and 30 (21.1%) were non-
Beijing isolates. Substitution of serine with leucine
at codon 531 was the most frequent mutation
found among both Beijing isolates (62 ⁄ 112; 55.4%)
and non-Beijing isolates (21 ⁄ 30; 70%); the higher
frequency of mutation among the non-Beijing
isolates was not statistically signiﬁcant (p 0.148).
The second most common mutation occurred at
codon 526 (25.9% among Beijing isolates and
23.3% among non-Beijing isolates; p 0.775). Sim-
ilarly, there was no signiﬁcant difference in the
occurrence of mutations at codon 516 between the
Beijing and non-Beijing isolates (9.8% and 3.3%,
respectively; p 0.257).
Of 11 rifampicin-mono-resistant isolates, nine
(81.8%) were Beijing isolates. The Ser ﬁ Leu
mutation at codon 531 was found at a higher
frequency among isolates with this genotype than
Table 3. Distribution and frequency of rpoB mutations
among 142 multidrug-resistant Mycobacterium tuberculosis
(MDRTB) isolatesa
rpoB mutations
(no. of isolates, %)
No. of isolates
Beijing Non-Beijing
Single mutation (135, 94.4)
531 TCG ﬁ TTG (Ser ﬁ Leu) (82, 57.3) 62 20
526 CAC ﬁ TAC (His ﬁ Tyr) (18, 12.6) 12 6
CAC ﬁ CTC (His ﬁ Leu) (6, 4.2) 6 0
CAC ﬁ GAC (His ﬁ Asp) (5, 3.5) 4 1
CAC ﬁ CGC (His ﬁ Arg) (4, 2.8) 4 0
516 GAC ﬁ GTC (Asp ﬁ Val) (11, 7.7) 11 0
513 CAA ﬁ CCA (Gln ﬁ Pro) (1, 0.7) 1 0
CAA ﬁ AAA (Gln ﬁ Lys) (1, 0.7) 0 1
CAA ﬁ GAA (Gln ﬁ Glu) (1, 0.7) 1 0
522 TCG ﬁ TTG (Ser ﬁ Leu) (1, 0.7) 1 0
533 CTG ﬁ CCG (Leu ﬁ Pro) (3, 2.1) 3 0
146 GTC ﬁ TTC (Gln ﬁ Lys) (2, 1.4) 2 0
Double mutations ⁄deletions (8, 5.6)
531 ⁄ 622 TCG ﬁ TTG (Ser ﬁ Leu) ⁄
TCG ﬁ GCG (Ser ﬁ Ala) (1, 0.7)
0 1
526 ⁄ 515 CAC ﬁ AGC (His ﬁ Ser) ⁄
ATG ﬁ CTG (Met ﬁ Val) (1, 0.7)
1 0
526 ⁄ 535 CAC ﬁ AGC (His ﬁ Ser) ⁄
CCC ﬁ CAC (Pro ﬁ His) (1, 0.7)
1 0
526 ⁄ 541 CAC ﬁ TAC (His ﬁ Tyr) ⁄
GAG ﬁ GGG (Glu ﬁ Gly) (1, 0.7)
1 0
516 ⁄ 511 GAC ﬁ TAC (Asp ﬁ Tyr) ⁄
CTG ﬁ CGG (Leu ﬁ Arg) (1, 0.7)
ND ND
516 ⁄ 522 GAC ﬁ GAG (Asp ﬁ Glu) ⁄
TCG ﬁ TTG (Ser ﬁ Leu) (1, 0.7)
0 1
Del 513–514 (ATTCATGGA) (1, 0.7) 1 0
Del 518–519 (CAA) (1, 0.7) 1 0
Total 112 30
ND, not determined (i.e., no spoligotyping result was obtained).
aOne additional MDRTB isolate was not available for spoligotyping.
Table 4. Distribution and frequency of the rpoB mutations
among 11 rifampicin-mono-resistantM. tuberculosis isolates
rpoB mutations (no. of isolates, %)
No. of isolates
Beijing Non-Beijing
Single mutation (11, 100)
531 TCG ﬁ TTG (Ser ﬁ Leu) (4, 36.4) 4 0
526 CAC ﬁ TAC (His ﬁ Tyr) (4, 36.4) 2 2
CAC ﬁ CGC (His ﬁ Arg) (1, 9.1) 1 0
516 GAC ﬁ GTC (Asp ﬁ Val) (1, 9.1) 1 0
146 GTC ﬁ TTC (Gln ﬁ Lys) (1, 9.1) 1 0
Total 9 2
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the codon 526 mutation (44.4% vs. 33.3%). How-
ever, the number of isolates was too small for
statistical analysis. The two remaining non-Beijing
isolates both contained a His ﬁ Tyr substitution
at codon 526.
Rapid identiﬁcation of mutations by MAS-PCR
The PCR-based method combining the M. tuber-
culosis complex-speciﬁc primers and the rpoB
allele-speciﬁc primers was established to detect
mutations associated with rifampicin resistance.
The detection limit of MAS-PCR was determined
by testing varying concentrations of M. tuberculo-
sis H37Rv puriﬁed DNA (100 ng to 100 fg). The
results revealed that the MAS-PCR could identify
mutations with 100 pg of DNA template, equiv-
alent to c. 20 000 mycobacterial cells (results not
shown).
In total, 216 of the M. tuberculosis isolates
included in this study were randomly selected
for analysis by MAS-PCR; the selected isolates
included 113 rifampicin-susceptible and 103 rif-
ampicin-resistant isolates. The results obtained
were compared to those obtained using the
proportion method, which was used as the
reference standard. The MAS-PCR identiﬁed 119
isolates as rifampicin-susceptible and 97 as rifam-
picin-resistant, including three isolates with dis-
tinct band patterns (Table 5). MAS-PCR wrongly
identiﬁed six resistant isolates as rifampicin-
susceptible. Analysis of rpoB gene sequences for
all six isolates wrongly identiﬁed as susceptible
and the three isolates with distinct band patterns
revealed that the ﬁrst six isolates contained
mutations either within or outside the hot-spot
region (codon 176 or codon 533). Of the three
isolates with distinct band patterns, two had
deletions and one had a double mutation. Exam-
ples of the results obtained are shown in Fig. 2.
Compared to the proportion method, the sensi-
tivity, speciﬁcity, PPV and NPV of MAS-PCR
were 94.2%, 100%, 100% and 95%, respectively.
DISCUSSION
Many rapid genetic methods have now been
developed for early detection of MDRTB. All of
these methods are based on identiﬁcation of rpoB
mutations conferring rifampicin resistance. The
present study revealed that the Beijing genotype
Table 5. Results of the multiplex allele-speciﬁc (MAS-






Resistant 97 0 97
Susceptible 6 113 119
Total 103 113 216









bp  bp  
Fig. 2. Examples of the results obtained using the multiplex allele-speciﬁc (MAS)-PCR method. Lanes: M, 25-bp DNA
ladder; 1–4, Mycobacterium tuberculosis isolates with a mutation at codon 531; 5, rifampicin-susceptible isolate; 6 and 7,
isolates with a mutation at codon 526; 8 and 9, isolates with a mutation at codon 516; 10, isolate with a double mutation at
codons 511 and 516; 11, isolate with a deletion between codons 513 and 516; 12–14, rifampicin-susceptible isolates; 15, 1 ng
of puriﬁed M. tuberculosis H37Rv DNA (positive control); 16, positive internal marker generated by mixing the ampliﬁed
products of each primer pair.
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was predominant (79.1%) among rifampicin-
resistant isolates in Thailand, particularly when
compared with susceptible isolates (45.5%,
p <0.001). This ﬁnding accords with previous
ﬁndings that this genotype is now distributed
worldwide, particularly in Southeast Asia, East
Asia, and the former Soviet Union, and is likely to
be associated with MDRTB [18,19,23,32,33]. The
genotyping results for the susceptible M. tubercu-
losis isolates in the present study also revealed an
increasing prevalence of the Beijing genotype
(45.5% compared with 20.7% in 1997–1998).
The present study revealed that 100% of Thai
rifampicin-resistant (mostly MDRTB) isolates con-
tained mutations in the rpoB gene; 94.8% of these
mutations were single substitutions and 5.2%
were double substitutions. In accord with previ-
ous studies [9,34–41], codon 531 was the most
common site of mutation (58% of the MDRTB
isolates). As in previous studies [13,15], the
mutational frequency was higher in non-Beijing
isolates, but this was not statistically signiﬁcant
(70% vs. 55.4%, p 0.148).
Mutations at codons 526 and 516 have been
shown to occur at different frequencies in isolates
from different geographical regions. Studies from
East Asia [16] and Latvia [8], where the Beijing
genotype is predominant, have revealed higher
mutational frequencies in codon 516 (15–32%)
than in codon 526 (10–20%). In contrast, the
present study revealed that mutations occurred at
codons 526 and 516 in 25.2% and 9.1% of the
MDRTB isolates, respectively. This observation is
in accord with recent reports from Taiwan, where
the mutation frequency at codon 526 was higher
than that at codon 516 [40,41]. This indicates the
possibility of variation in isolates from different
geographical regions. Substitution of leucine with
proline at codon 533 was found in 2.1% of
isolates; substitution of glutamine at codon 513
was also found in 2.1% of isolates, but with
different amino-acids. In addition, mutation of
codon 146 in the N-terminal part of the rpoB gene
occurred in 1.4% of isolates. These mutational
frequencies are similar to those reported in
previous studies [6,36–39,41].
Interestingly, there were differences between
the MDRTB and the rifampicin-mono-resistant
isolates, with the prevalence of mutations at
codon 526 being higher than that at codon 531
in the rifampicin-mono-resistant population
(45.4% vs. 36.4%). However, the number of
isolates was too small to allow deﬁnitive conclu-
sions. There may be other factors in the genetic
backgrounds of MDRTB and mono-resistant iso-
lates that play a role in differential selection of the
mutated codon in the presence of the drug.
Alternatively, mutations at these two sites may
occur independently without bias, because muta-
tions at both codons 531 (Ser ﬁ Leu) and 526
(His ﬁ Tyr, His ﬁ Asp and His ﬁ Arg) have
been shown to have a minimal ﬁtness cost in
comparison with the wild-type susceptible strain
[42,43].
All of the Thai MDRTB isolates had mutations
in the rpoB gene, and 88% of these mutations
were located in three codons (531, 526 and 516).
The allele polymorphism and prevalence of dou-
ble mutations was low. This epidemiological
information enabled the development of a geno-
typic method for identifying drug-resistant iso-
lates. MAS-PCR targeting ﬁve loci was used to
detect rifampicin-resistant M. tuberculosis isolates
in a single tube, and showed 94.2% sensitivity,
100% speciﬁcity, 100% PPV and 95% NPV
compared with the phenotypic method, and
100% concordance with sequencing results. How-
ever, false-negative results could occur when
testing isolates carrying unusual mutations;
hence, results indicating susceptibility should be
interpreted with caution. An additional limitation
concerned the appearance of some non-speciﬁc
bands when crude DNA extract was used as
template, and it is important to use the M. tuber-
culosis complex-speciﬁc band as an internal con-
trol to monitor the presence of any PCR inhibitors.
Nevertheless, the present study demonstrated the
usefulness of this method for preliminary detec-
tion of MDRTB and for providing epidemiological
data. In addition, the ease of use and low cost of
this technique indicated that MAS-PCR could be
useful for resource-limited countries with a high
burden of TB.
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